Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions rather than a financial performance report.
Material Changes
The material change reported is the partial vesting of a Performance Share Plan award made in 2004 to a connected person of Dr. M. Slaoui, a Person Discharging Managerial Responsibility. This transaction resulted in the vesting of 946 Ordinary shares, while the balance of the original award lapsed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: February 21, 2008.
- Individual Involved: Dr. M. Slaoui (via a connected person).
- Transaction Type: Partial vesting of a 2004 Performance Share Plan award.
- Shares Affected: 946 Ordinary shares vested; remainder of the award lapsed.
- Signatory: Victoria Whyte, Authorised Signatory.